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INTRODUCTION 
The emergence of severe acute respiratory syndrome coro-
navirus (SARS-CoV) in 2003 led to more than 8,000 infec-
tions and 800 deaths (1, 2). In 2019, SARS-CoV-2 emerged in 
Wuhan, China (3). The spread of SARS-CoV-2, the virus that 
causes coronavirus disease 2019 (COVID-19) was rapid. By 
March 2020, the World Health Organization (WHO) had de-
clared the SARS-CoV-2 outbreak a global pandemic. By Octo-
ber 2021, more than 200 million people had been infected 
globally, resulting in over 4.5 million deaths. This was associ-
ated with the documented emergence of several SARS-CoV-2 
variants which can partially evade host immunity. Therefore, 
there is a need to develop safe and effective broad-spectrum 
countermeasures that can prevent the rapid spread and at-
tenuate the severe disease outcomes associated with current 
and future SARS-related virus emergence events. 
Highly pathogenic coronavirus outbreaks in humans are 
likely of bat origin (4), and there is great genetic diversity 
among bat SARS-related viruses (5). Zoonotic coronaviruses 
of bat origin, such as RsSHC014 and WIV-1, can utilize the 
human angiotensin converting enzyme 2 (ACE2) receptor for 
cell entry and can infect human airway cells (6, 7), highlight-
ing their potential for emergence in naïve human popula-
tions. Moreover, existing therapeutic monoclonal antibodies 
against SARS-CoV, and SARS-CoV-2 mRNA vaccines do not 
fully protect against zoonotic SARS-related virus infection in 
vivo (6–8). Given the pandemic potential of SARS-related vi-
ruses, the development of broadly effective countermeasures, 
such as universal vaccination strategies (8–10) and corona-
virus cross-reactive monoclonal antibodies, is a global health 
priority. Moreover, given the emergence of the SARS-CoV-2 
variants that are partially or fully resistant to some neutral-
izing antibodies authorized for COVID-19 treatment (11–13), 
there is a need to develop mAb therapies that are broadly ef-
fective against existing SARS-CoV-2 variants and zoonotic 
SARS-related viruses that may emerge in the future. 
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Severe acute respiratory syndrome coronaviruses 1 (SARS-CoV) and 2 (SARS-CoV-2), including SARS-CoV-
2 variants of concern, can cause deadly infections. The mortality associated with sarbecovirus infection 
underscores the importance of developing broadly effective countermeasures against them, which could be 
key in the prevention and mitigation of current and future zoonotic events. Here, we demonstrate the 
neutralization of SARS-CoV, bat coronaviruses WIV-1, RsSHC014, and SARS-CoV-2 variants D614G, B.1.1.7, 
B.1.351, P.1, B.1.429, B.1.526, B.1.617.1, and B.1.617.2 by a receptor-binding domain (RBD)-specific human 
antibody, DH1047. Prophylactic and therapeutic treatment with DH1047 was protective against SARS-CoV, 
WIV-1, RsSHC014, and SARS-CoV-2 B.1.351 infection in mice. Binding and structural analysis showed high 
affinity binding of DH1047 to an epitope that is highly conserved among sarbecoviruses. Thus, DH1047 is a 
broadly protective antibody that can prevent infection and mitigate outbreaks caused by SARS-related 
strains and SARS-CoV-2 variants. Our results also suggest that the conserved RBD epitope bound by 
DH1047 is a rational target for a universal sarbecovirus vaccine.
The receptor binding domain (RBD) of SARS-CoV-2 is one 
of the targets for highly potent neutralizing antibodies. De-
spite the high degree of genetic diversity within the RBD in 
SARS-related viruses (5), antibodies can be engineered to rec-
ognize diverse SARS-related viruses. Rappazzo et al. recently 
reported that an engineered RBD-directed antibody, ADG-2, 
neutralized SARS-related viruses and protected against 
SARS-CoV and wild type SARS-CoV-2 (14). Therefore, the 
RBD of sarbecoviruses contains conserved epitopes that are 
the target of broadly neutralizing antibodies. In agreement 
with the notion that the RBD contains a conserved epitope 
shared among SARS, SARS-related, SARS-CoV-2 and the var-
iants, we have identified a coronavirus cross-reactive RBD 
protective antibody: DH1047 (15). 
RESULTS 
The identification of broadly cross-binding and neu-
tralizing antibodies 
We previously isolated 1737 monoclonal antibodies 
(mAbs) from a SARS-CoV convalescent patient 17 years fol-
lowing infection and from a SARS-CoV-2 convalescent patient 
36 days post infection (15). From this large panel of mAbs 
previously described by Li et al. we focused on 50 cross-reac-
tive antibodies that bound to SARS-CoV, SARS-CoV-2, and 
other human and animal coronavirus antigens from genet-
ically distinct sarbecoviruses. Importantly, sarbecoviruses 
vary in their ability to utilize human ACE2 and exhibit sub-
stantial genetic diversity in their RBDs (Fig. 1A) (15). To ex-
amine if these 50 cross-neutralizing mAbs neutralized 
pandemic and zoonotic sarbecoviruses, we measured neutral-
izing activity against a mouse-adapted SARS-CoV-2 (MA) vi-
rus, SARS-CoV, bat CoV WIV-1, and bat CoV RsSHC014 using 
live viruses. We identified four broadly cross-reactive anti-
bodies, DH1235, DH1073, DH1046, and DH1047 (Fig. 1B to E). 
We focused our analyses on these four antibodies, as they had 
broad neutralization. DH1235 neutralized SARS-CoV-2 2AA 
MA, SARS-CoV, and bat coronavirus WIV-1 with half-maxi-
mal inhibitory concentration (IC50) of 0.122, 0.0403, and 
0.060 μg/ml, respectively (Fig. 1B and table S1). DH1073 neu-
tralized SARS-CoV-2 2AA MA, SARS-CoV, bat coronaviruses 
WIV-1 and RsSHC014 with IC50 of 0.808, 0.016, 0.267, and 1.32 
μg/ml, respectively (Fig. 1C and table S1). DH1046 neutralized
SARS-CoV-2 2AA MA, SARS-CoV, bat coronaviruses WIV-1 
and RsSHC014 with IC50 of 2.85, 0.103, 0.425, and 1.27μg/ml,
respectively (Fig. 1D and table S1). DH1047 was the most po-
tent, and neutralized SARS-CoV-2 2AA MA, SARS-CoV, bat 
coronaviruses WIV-1 and RsSHC014 with IC50 of 0.397, 0.028, 
0.191, and 0.200μg/ml, respectively (Fig. 1E and table S1). As
our study goal was to characterize the protective efficacy of 
cross-reactive antibodies, we compared the neutralization ac-
tivity of DH1047 to two other mAbs currently in clinical trials, 
the cross-reactive ADG-2 (Adagio Therapeutics Inc, Adimab) 
and the potent REGN 10933 (Regeneron Pharmaceuticals), 
against SARS-CoV-2 B.1.351, SARS-CoV urbani, and 
RsSHC014 (fig. S1). Notably, ADG-2 was engineered for in-
creased potency whereas DH1047 was not (14). REGN 10933 
had reduced neutralizing activity against SARS-CoV-2 B.1.351 
compared to both ADG-2 and DH1047 (fig. S1). Like DH1047, 
ADG-2 effectively neutralized SARS-CoV urbani whereas 
REGN 10933 did not. Last, both ADG-2 and DH1047 neutral-
ized RsSHC014 whereas REGN 10933 did not (fig. S1). 
To focus our screen on the four broadly neutralizing 
mAbs, we measured binding responses for DH1235, DH1073, 
DH1046, and DH1047 against other zoonotic bat spike pro-
teins including RaTG13-CoV, bat RsSHC014, and against the 
spike protein of Pangolin GXP4L-CoV. DH1235, DH1073, 
DH1046, and DH1047 mAbs showed strong binding to bat 
RaTG13-CoV, bat RsSHC014, and pangolin GXP4L-CoV spike 
proteins in addition to SARS-CoV and SARS-CoV-2 (Fig. 2A 
to D). DH1235, DH1073, DH1046, and DH1047 bound to 
SARS-CoV-2 RBD and did not bind to the SARS-CoV-2 NTD. 
Although DH1235, DH1073, DH1046, and DH1047 were cross-
reactive against epidemic, pandemic, and zoonotic sarbe-
covirus spike proteins, they did not bind to MERS-CoV, Hu-
CoV OC43, HuCoV NL63, or HuCoV 229E spike proteins (fig. 
S2), suggesting these mAbs recognize a conserved epitope 
found only in Group 2B betacoronaviruses. 
To examine if these cross-reactive mAbs shared any over-
lap in their epitopes, we examined their binding footprint by 
both negative stain electron microscopy (NSEM) and surface 
plasmon resonance (SPR). DH1047 had an overlap with 
DH1235 but not with DH1073 and had different angles of ap-
proach to the SARS-CoV-2 spike protein (fig. S3A to C). More-
over, from SPR competition experiments, DH1047, DH1046, 
and DH1235 were outcompeted by one another (fig. S3D), 
whereas DH1073 was not, indicating that DH1073 targets a 
distinct non-cross-competing epitope. As DH1047 was the 
most potent mAb out of the four cross-reactive mAbs in our 
screen, we also performed NSEM, and observed binding of 
DH1047 to the RBD of bat RsSHC014 and SARS-CoV spike 
ectodomains, with overall similar orientations as was ob-
served for DH1047 binding to the SARS-CoV-2 spike ectodo-
main (fig. S4) (15). A 3.20 Å cryo-EM structure of DH1047 
bound to the SARS-CoV spike protein showed three DH1047 
Fab bound to each of the 3 RBD of the ectodomain in the “up” 
position (1 Fab:1 RBD ratio) (Fig. 2E, fig. S5, and table S2). 
DH1047 binding to the SARS-CoV RBD involved interactions 
between the antibody heavy-chain-complementarity-deter-
mining-region 3 (HCDR3) and residues 356 to 372 of the RBD, 
and of the light-chain-complementarity-determining-region 1 
(LCDR1) and LCDR3 regions with the RBD region spanning 
residues 390 to 404. The LCDR3 also interacted with recep-
tor-binding motif (RBM) residues 488 to 492. The angle of 
approach and footprint of DH1047 on the SARS-CoV RBD 
closely resembled that in the SARS-CoV-2 complex (15) with 
steric overlap predicted with ACE2 binding (Fig. 2E). These 
results demonstrate that DH1047 binds to SARS-CoV and 
SARS-CoV-2 spike ectodomains by involving homologous in-
teractions (Fig. 2F), consistent with our analysis of RBD se-
quence variability that showed a high degree of convergence 
of the DH1047 epitope (Fig. 2F) (9), thereby defining an RBD 
conserved site of vulnerability in sarbecoviruses. 
We also defined the binding affinity of DH1047 against 
epidemic and zoonotic spike proteins. We measured binding 
on and off rates against both SARS-CoV and RsSHC014-CoV 
spike proteins by SPR. DH1047 bound to the SARS-CoV and 
RsSCH014-CoV spike proteins with high affinity, association 
rates (> 8.60 X104 M−1s−1) and dissociation rates (< 1.0X10−5 
s−1) (fig. S6), demonstrating that DH1047 binds tightly to both 
the epidemic SARS-CoV and pre-emergent bat coronavirus 
spike proteins. Finally, DH1235, DH1073, DH1046, and 
DH1047 exhibited medium to long HCDR3 lengths and vari-
able nucleotide somatic mutation rates in the heavy chain 
genes. DH1235, DH1073, and DH1046, had HCDR3 lengths of 
21, 15, and 24, and nucleotide somatic hypermutation (SMH) 
rates of 1.7, 9.0, and 4.7, respectively (table S3). The most po-
tent neutralizing antibody DH1047 had HCDR3 lengths and 
SMH rates of 24 and 8.05, respectively (table S3). 
The protective activity of DH1235, DH1073, 
DH1046, and DH1047 against SARS-CoV 
To define the protective efficacy of these four cross-reac-
tive and broadly neutralizing RBD-specific IgG bNAbs, we 
passively immunized aged mice with DH1235, DH1073, 
DH1046, DH1047 and a negative control influenza mAb, 
CH65 (16), at 10mg/kg 12 hours prior to infection with SARS-
CoV mouse-adapted passage 15 (MA15) and evaluated lung 
viral titer replication. Demonstrating a disconnect between 
in vitro and in vivo protection, neither DH1235, DH1073, nor 
DH1046 protected SARS-CoV MA15 challenge in mice and all 
had lung viral replication comparable to that of control mice 
(Fig. 3A). In contrast, prophylactic administration of DH1047 
fully protected mice from lung viral titer replication (Fig. 3A). 
Given the prophylactic potential of DH1047, we sought to also 
evaluate its therapeutic potential in this mouse model. We 
treated mice with control mAb or DH1047 at 10mg/kg either 
at 12 hours before or 12 hours post infection with SARS-CoV 
MA15 and monitored mice for signs of clinical disease, includ-
ing weight loss and pulmonary function, which was meas-
ured by whole-body plethysmography (Buxco), through day 4 
post infection (4dpi). In agreement with the earlier SARS-
CoV MA15 experiment, prophylactic treatment with DH1047 
protected mice from weight loss through 4dpi (Fig. 3B) and 
lung viral replication (Fig. 3C). Similarly, DH1047 therapy at 
12 hours post infection resulted in reduced lung viral titers 
(Fig. 3C and fig. S7) as well as the macroscopic lung damage 
measured by the lung discoloration score (Fig. 3D and fig. S7). 
We also evaluated if the prophylactic and therapeutic 
administration of DH1047 protected against lung pathology 
as measured by lung discoloration, which is a visual metric 
of gross lung damage taken at the time of the necropsy, mi-
croscopic evaluation as measured by an acute lung injury 
(ALI) scheme, and a diffuse alveolar damage (DAD) scheme. 
ALI and DAD, which are characterized by histopathologic 
changes including alveolar septal thickening, protein exudate 
in the airspace, hyaline membrane formation, and neutro-
phils in the interstitium or alveolar sacs, were both blindly 
evaluated by a board-certified veterinary pathologist blinded 
to the groups. The prophylactic administration of DH1047 re-
sulted in complete protection from macroscopic lung discol-
oration (Fig. 3D) and microscopic lung pathology as 
measured by ALI (Fig. 3E and fig. S7) and DAD (Fig. 3F and 
fig. S7). In contrast to the prophylactic treatment condition, 
therapeutic administration of DH1047 did not reduce micro-
scopic lung pathology compared to control mice as measured 
by ALI (Fig. 3E and fig. S7) and DAD (Fig. 3F and fig. S7) in 
this highly vulnerable model for SARS-CoV pathogenesis. The 
prophylactic and therapeutic administration of DH1047 pre-
vented degradation of pulmonary function compared to con-
trols (Fig. 3G). Finally, both the prophylactic and therapeutic 
administration of DH1047 resulted in complete survival of in-
fected mice, whereas only 50% of control mice survived (Fig. 
3H). Thus, DH1047 can prevent SARS-CoV disease when ad-
ministered prophylactically and has measurable therapeutic 
benefits in a highly susceptible aged mouse model. 
DH1047 has prophylactic and therapeutic activity 
against bat pre-emergent coronaviruses and neutral-
izes SARS-CoV-2 variants in vitro. 
As DH1047 neutralized both WIV-1 and RsSHC014 (Fig. 1), 
we sought to define if DH1047 had prophylactic and thera-
peutic efficacy in mice against these pre-emergent bat coro-
naviruses. We administered DH1047 prophylactically 12 
hours before infection and therapeutically 12 hours post in-
fection at 10mg/kg in mice infected with bat coronaviruses. 
Prophylactic administration of DH1047 completely protected 
mice from WIV-1 lung viral replication and reduced lung viral 
titers in therapeutically treated mice compared to control 
mice (Fig. 4A). Similarly, prophylactic administration of 
DH1047 completely protected mice from RsSHC014 lung viral 
replication and reduced viral replication to near undetectable 
concentrations in therapeutically treated mice (Fig. 4B). Alt-
hough we previously demonstrated the prophylactic and 
therapeutic efficacy of DH1047 against the SARS-CoV-2 Wu-
han isolate in cynomolgus macaques (15), which exhibit mild 
SARS-CoV-2 disease (17), it was not known if the mutations 
present in the newly emerging SARS-CoV-2 variants would 
ablate the neutralizing activity of DH1047. We therefore eval-
uated if DH1047 could neutralize the prevalent variants of 
concern using both pseudovirus and live virus neutralization 
assays. DH1047 neutralized all tested variants of concern 
including SARS-CoV-2 D614G, B.1.1.7 (Alpha), B.1.351 (Beta), 
P.1 (Gamma), B.1.429, B.1.526, B.1.617.1 (Kappa), and B.1.617.2
(Delta) (Fig. 4C and Fig. 4D). The pseudovirus 50% neutrali-
zation assay (PsVNA50) values against all the variants ranged
between 0.1214 and 0.1609 μg/ml, confirming broad neutral-
ization of SARS-CoV-2 variants of concern by DH1047 (Fig. 
4D). Live virus neutralization also demonstrated the broadly 
neutralizing activity of DH1047, with IC50 values against 
D614G, B.1.1.7, and B.1.351 measured at 0.059, 0.081, and 
0.111μg/ml, respectively.
The prophylactic and therapeutic activity of 
DH1047 against SARS-CoV-2 B.1.351 in mice 
Given that the B.1.351 variant is more resistant to both 
vaccine-elicited neutralizing antibodies (11, 18), and com-
pletely ablates the neutralizing activity of the Eli Lilly thera-
peutic monoclonal antibody, LY-CoV555 (13), we also sought 
to evaluate if DH1047 had prophylactic or therapeutic effi-
cacy against SARS-CoV-2 B.1.351 in mice. We again utilized a 
highly susceptible and vulnerable aged mouse model in the 
SARS-CoV-2 B.1.351 protection experiments. Consistent with 
the SARS-CoV, WIV-1, and RsSHC014 in vivo data, prophylac-
tic administration of DH1047 mediated complete protection 
against severe weight loss following SARS-CoV-2 B.1.351 chal-
lenge in aged mice (Fig. 5A). In contrast, we did not observe 
differences in weight loss after the therapeutic administra-
tion of DH1047 as compared to controls (Fig. 5A). Mice 
prophylactically treated with DH1047 had undetectable 
SARS-CoV-2 B.1.351 lung viral replication (Fig. 5B) and were 
also completely protected from macroscopic lung pathology 
compared to controls (Fig. 5C). Therapeutic administration 
of DH1047 resulted in a reduction in lung viral titers com-
pared to control (Fig. 5B). We also evaluated the microscopic 
lung pathology as measured by ALI (Fig. 5D) and DAD scor-
ing (Fig. 5E) schemes in this susceptible aged model for 
SARS-CoV-2 B.1.351 pathogenesis. Prophylactic administra-
tion of DH1047 protected mice from lung histopathology as 
measured by ALI and DAD compared to control mice. Addi-
tionally, we observed a reduction in ALI by the therapeutic 
administration of DH1047 as measure by macroscopic lung 
pathology (Fig. 5C) and lung histopathology (Fig. 5D). Finally, 
there was no difference in mortality in the SARS-CoV-2 
B.1.351 challenge model in the control and DH1047-treated
mice (Fig. 5F). Therefore, DH1047 can prevent and treat
SARS-CoV-2 infections with the B.1.351 variant of concern in
vivo. To determine the concentration at which we observe
breakthrough infection in vivo, we performed a dose de-esca-
lation study and treated mice prophylactically at 10, 5, and
1mg/kg. We observed full protection in mice treated with the
10mg/kg dose but not in mice treated with the 5mg/kg dose,
measured by weight loss and lung discoloration, despite full
protection lung viral replication compared to control (Fig. 5G
to I). In contrast, incomplete protection from weight loss,
breakthrough viral lung replication, and lung pathology was 
observed at the 1mg/kg prophylaxis dose of DH1047 (Fig. 5G 
to I). 
The structural comparison of DH1047 to other anti-
bodies targeting the RBD 
Comparing the DH1047 epitope with that of representa-
tive RBD-directed antibodies from Class 1, 2, 3 and 4 (19), we 
found that the DH1047 footprint overlapped with antibody 
C105 (Class 1) and CR3022 (Class 4) (Fig. 5J and fig. S8). The 
DH1047 footprint on the RBD showed similarity with Ab 
H014 (20) and overlapped with the footprint of other anti-
bodies whose epitopes overlap with that of CR3022 (21–23). 
The classification of RBD-directed antibodies has recently 
been re-defined to include a larger set of antibodies and finer 
epitope binning (24). DH1047 classifies in the RBD-6 category 
in this new system based on overlap of its footprint with 
CR3022, proximity to RBD-2a antibodies (such as REGN-
10933), and its ability to compete with ACE2 binding (15). In-
terestingly, single domain antibodies, or nanobodies, that po-
tently neutralize SARS-CoV-2 show a close overlap with the 
DH1047 VH domain (fig. S8). Nanobody VHH V shows the 
closest overlap with its elongated HCDR3 loop binding to a 
similar RBD region as the HCDR3 of DH1047. We performed 
alanine scanning mutagenesis of the DH1047 HCDR3 resi-
dues proximal to the RBD epitope (fig. S9). Mutating residue 
Trp100B to Ala did not alter its binding to the ectodomain of 
SARS-CoV-2 spike protein stabilized with the two prolines (S-
2P), consistent with the orientation of the Trp side chain 
away from the epitope. Similarly, mutating residues Ser100A 
and Ser100C to Ala did not alter binding. Ala mutants of res-
idues Leu100G and Asp100F notably reduced DH1047 bind-
ing to the spike protein even though these residues did not 
directly contact the RBD, possibly by disrupting the confor-
mation of the long HCDR3 loop. Mutagenesis of the LCDR3 
similarly resulted in notable reduction in binding observed 
for Tyr91Ala and Arg96Ala substitutions, although neither of 
these residues directly contacted the RBD. Reduction in bind-
ing was also observed for Ala substitution of residue Leu94 
where the Leu side chain occupied a hydrophobic pocket 
formed by the heavy chain residues Leu100G and Ile58, and 
RBD residue Val394. 
The DH1047 epitope also overlaps with that of antibody 
ADG-2, which was previously shown to neutralize SARS-
related viruses and protecting against SARS-CoV and SARS-
CoV-2 (14). The approach angles of DH1047 and ADG-2 differ, 
with a rotation about the Fab longitudinal axis pivoting the 
ADG-2 antibody more toward the ACE2 binding region com-
pared to DH1047 (fig. S10A and B). In contrast to ADG-2 
which uses VH3-21 for its heavy chain and has a 17 amino 
acid long HCDR3, DH1047 uses VH1-46 and has a 24 amino 
acid long HCDR3 (table S3) (14). To compare the therapeutic 
efficacy of DH1047 against ADG-2, we performed a head-to-
head comparison study. Aged mice were therapeutically 
treated with either DH1047, ADG-2, or CH65 control mAbs at 
10mg/kg at 6 hours post infection with SARS-CoV-2 B.1.351. 
Mice treated with either DH1047 or ADG-2 were completely 
protected from weight loss, lung viral replication, and lung 
damage compared to controls (fig. S10C), suggesting that 
DH1047 has similar in vivo therapeutic profiles to ADG-2, 
which is another potent cross-protective mAb (14). 
DISCUSSION 
The emergence of SARS-CoV and SARS-CoV-2 in the last 
two decades underscores a critical need to develop broadly 
effective countermeasures against sarbecoviruses. Moreover, 
with the recent emergence of the more transmissible (25), 
modestly more virulent (26) B.1.1.7 variant (Alpha), B.1.351 
(Beta), B.1.1.28 (Gamma), and the highly transmissible 
B.1.617.2 variant (Delta), all of which can partially evade ex-
isting countermeasures (11, 13, 27), there is a need to develop
next-generation mAb therapeutics that can broadly neutral-
ize these variants, as well as future variants of concern. For
example, the SARS-CoV-2 B.1.351 variant completely ablates
the neutralization activity of the mAb LY-CoV555 (13, 28). As
a result, the emergency use authorization (EUA) of LY-
CoV555 was recently rescinded by the U.S. Food and Drug
Administration (FDA). In addition, the presence of the E484K
mutation in many variants of concern, severely dampens the
neutralization activity by more than 6-fold of the AstraZeneca
COV2-2196 mAb, Brii BioSciences Brii-198 mAb, and the Re-
generon REGN 10933 mAb (11, 28). In addition to evading
currently monoclonal antibody therapeutics, some of the var-
iants including B.1.351 can diminish the efficacy of clinically
approved vaccines, including the Johnson & Johnson single-
dose vaccine and the AstraZeneca ChAdOx1 nCoV-19 vaccine
(29, 30). Furthermore, some monoclonal antibodies isolated
from vaccine recipients of the Moderna mRNA-1273 and
Pfizer/BioNTech BNT162b2 vaccines also demonstrated re-
duced efficacy against mutations present in the variants (31).
Therefore, current vaccine and mAb therapies must be mon-
itored in real time to define the performance of existing ther-
apies against newly emerging and spreading variants. In the
setting of reduced vaccine efficacy, the deployment of mAb
therapies that are effective against variants, such as DH1047,
could be a strategy to help control the COVID-19 pandemic.
The development of universal vaccination strategies 
against sarbecoviruses will be improved by the identification 
and characterization of broadly protective and conserved 
epitopes across SARS-related virus strains. Several SARS-
related cross-reactive antibodies were recently described. For 
example, RBD-specific antibody, S2X259, neutralized SARS-
CoV-2 variants and zoonotic SARS-related viruses, as meas-
ured by pseudovirus neutralization (32) and another RBD-
specific antibody had broad protection against the SARS-
CoV-2 variants (33). Similarly, a recent subset of RBD-specific 
cross-reactive mAbs also showed in vitro activity (34), alt-
hough their in vivo breadth and protective efficacy against 
divergent sarbecoviruses remains unconfirmed. In contrast 
to DH1047, neither DH1235, DH1073, nor DH1046 fully pro-
tected against SARS-CoV infection in aged mice, possibly be-
cause these cross-reactive mAbs may have differences in their 
mechanisms of protection in vivo. Although it is not clear 
why these mAbs have in vivo protection differences, it is pos-
sible that they have differences in their angle of approach to 
the spike protein, require optimal Fc effector functions (35), 
or may have stability differences in vivo. 
DH1047 had broad protective in vivo efficacy against pre-
emergent SARS-related viruses, epidemic SARS-CoV, SARS-
CoV-2 B.1.351 variant, and neutralized all tested SARS-CoV-2 
variants including the delta variant, underscoring that 
DH1047 recognizes a pan-sarbecovirus neutralizing epitope. 
Consistent with this notion, we have described a SARS-CoV-
2 RBD-ferritin nanoparticle vaccine that elicited neutralizing 
antibodies against pre-emergent SARS-related viruses and 
protected against SARS-CoV-2 challenge in non-human pri-
mates (9). The serum antibody responses in these SARS-CoV-
2 RBD-ferritin nanoparticle-vaccinated monkeys could block 
DH1047 binding responses against SARS-CoV-2 spike pro-
teins, suggesting that SARS-CoV-2 RBD vaccines elicit 
DH1047-like antibody responses and could potentially pro-
tect against the future emergence of SARS-CoV or SARS-CoV-
2-related viruses. As other broad sarbecovirus vaccine formu-
lations are developed and following a recent study which re-
ported broad neutralization of sarbecoviruses in SARS
convalescent patients fully immunized with SARS-CoV-2
mRNA vaccines (8, 36), and it will be interesting to examine
if these vaccines and individuals generate DH1047-like neu-
tralizing antibodies.
Although we demonstrate the broad protective efficacy of 
DH1047 in mice, our study has limitations. First, our study 
does not evaluate the protective breadth of DH1047 against 
SARS-related viruses in larger animal models, such as non-
human primates. Second, our study does not evaluate the role 
of DH1047 Fc region modifications, such as those that more 
favorably interact with activating Fc receptors, in mediating 
protection against SARS-related viruses. Future studies 
should examine if the protective efficacy of DH1047 can be 
amplified by modulating Fc receptors in vivo. 
Moving forward, it will be critical to closely monitor 
SARS-CoV and SARS-CoV-2-related viruses of zoonotic origin 
and actively monitor if broad-spectrum antibodies like ADG-
2, DH1047, and S2X259 retain their inhibitory activity against 
pre-emergent viruses. We envision a system in which broad-
spectrum antibodies like DH1047 could be tested for safety in 
small Phase I clinical trials so that if a future SARS-related 
virus emerges, DH1047 could immediately be tested in larger 
efficacy trials at the site of an outbreak to potentially prevent 
the rapid spread of an emergent coronavirus. Moreover, given 
that DH1047 neutralized all tested SARS-CoV-2 variants in-
cluding the highly transmissible delta variant, this mAb could 
also be deployed now to help curb the ongoing COVID-19 
pandemic. Like other therapeutic monoclonal antibodies 
evaluated against COVID-19, our data suggest that early ad-
ministration will prove critical for protecting against severe 
disease outcomes (37). We conclude that DH1047 is a broadly 
protective mAb that has efficacy against pre-emergent, zoon-
otic SARS-related viruses from different clades, neutralizes 
highly transmissible SARS-CoV-2 variants of concern, and 
protects against SARS-CoV-2 B.1.351. 
MATERIALS AND METHODS 
Study design 
The study objective was to discover and characterize 
broadly neutralizing antibodies that are protective against di-
vergent SARS-related viruses. To this end, mAbs were tested 
in vitro to examine their binding and neutralizing activity 
and in vivo to measure their protective efficacy against multi-
clade sarbecoviruses. mAbs were tested in duplicate in neu-
tralization assays and experiments were repeated inde-
pendently for rigor and reproducibility. No statistical 
methods were used to predetermine mouse sample size. All 
mouse experiments utilized 5 to 10 mice per group. A control 
mAb-treated group was included in each independent exper-
iment for each different virus. No datapoints were excluded 
as outliers in any experiment. Naïve BALB/c mice (Envigo 
#047) were the same age (around 12 months) and sex (female) 
for the SARS-CoV MA15, RsSHC014, and SARS-CoV-2 B.1.351 
challenge experiments and were randomly assigned to the 
different mAb vs. control groups. Male and female eight to 
10-week-old hACE2-transgenic mice (B6J.Cg-Tg(FOXJ1-
ACE2)1Rba/Mmnc) bred at UNC Chapel Hill were equally dis-
tributed to the DH1047 and control mAb treatment groups
for the WIV-1 challenge experiments. Active animal biosafety
level 3 (BSL-3) experiments were not performed blindly. Fol-
lowing the completion of animal BSL-3 experiments and sam-
ple collection, all immunological, virological, and
histopathological measurements were performed blinded.
Immunological and virological samples were assigned new
numbers to blind researchers during readouts. Mice were eu-
thanized at day two post infection, which is peak lung viral
replication, to rigorously assess mAb-mediated protection
against lung viral infection. Mice were euthanized at day four
post infection, a time where signs of coronavirus disease are
set in these mouse models, to measure weight loss, lung viral
replication, lung pathology, pulmonary function, and mortal-
ity. All active mouse experiments were carried to completion
through day two or day four post infection except when mice
reached below 70 percent of their starting weight, a point in
which mice were humanely euthanized in accordance with
UNC Chapel Hill Institutional Animal Care and Use
Committee (IACUC)-approved protocols. Lung microscopic 
pathology readouts were performed by a board-certified vet-
erinary pathologist who was blinded to the treatment groups. 
Neutralization and SPR experiments for DH1047 and control 
were repeated twice independently with technical replicates 
in each experiment. DH1047 and CH65 control in vivo protec-
tion experiments against SARS-CoV MA15, RsSHC014, WIV-
1, and SARS-CoV-2 B.1.351 were repeated twice inde-
pendently. 
Biocontainment and biosafety 
Studies were approved by the UNC Institutional Biosafety 
Committee approved by animal and experimental protocols 
in the Baric laboratory. All work described here was per-
formed with approved standard operating procedures for 
SARS-CoV-2 in a BSL-3 facility conforming to requirements 
recommended in the Microbiological and Biomedical Labor-
atories, by the U.S. Department of Health and Human Ser-
vice, the U.S. Public Health Service, and the U.S. Center for 
Disease Control and Prevention (CDC), and the National In-
stitutes of Health (NIH). 
Antibody isolation and measurement of coronavirus 
spike protein binding by enzyme-linked immuno-
sorbent assay (ELISA) 
Monoclonal antibodies were isolated from antigen-spe-
cific single B cells from an individual who had recovered from 
SARS-CoV-1 infection 17 years prior to leukapheresis and 
from a SARS-CoV-2 convalescent individual 36 days post in-
fection as previously described (15). Monoclonal antibodies 
were screened by binding ELISAS. Indirect binding ELISAs 
were conducted in 384 well ELISA plates (Costar #3700) 
coated with 2μg/ml antigen in 0.1M sodium bicarbonate over-
night at 4°C, washed and blocked with assay diluent (1X 
phosphate buffered saline (PBS) containing 4% (w/v) whey 
protein, 15% normal goat serum, 0.5% Tween-20, and 0.05% 
sodium azide). mAbs were incubated for 60 min in three-fold 
serial dilutions beginning at 100 μg/ml followed by washing
with PBS/0.1% Tween-20. Horseradish peroxidase (HRP)-
conjugated goat anti-mouse IgG secondary antibody (South-
ernBiotech 1030-05) was diluted to 1:10,000 in assay diluent 
without azide, incubated at for 1 hour at room temperature, 
washed and detected with 20μl SureBlue Reserve (KPL 53-
00-03) for 15 min. Reactions were stopped via the addition of
20μl HCL stop solution. Plates were read at 450nm. Area un-
der the curve (AUC) measurements were determined from 
binding of serial dilutions. 
Measurement of neutralizing antibodies against 
live viruses 
Full-length SARS-CoV-2 Seattle, a mouse-adapted SARS-
CoV-2 2AA Q498Y/P499T, SARS-CoV-2 D614G, SARS-CoV-2 
B.1.351, SARS-CoV-2 B.1.1.7, SARS-CoV, WIV-1, and RsSHC014
viruses were designed to express nanoluciferase (nLuc) (8).
Virus titers were measured in Vero E6 (C1008) cells, as
defined by plaque forming units (PFU) per ml, in a 6-well 
plate format in quadruplicate technical replicates for accu-
racy. For the 96-well neutralization assay, Vero E6 (C1008) 
cells were plated at 20,000 cells per well the day prior in clear 
bottom black walled plates. Cells were inspected to ensure 
confluency on the day of assay. mAbs were serially diluted 
three-fold up to nine dilution spots at specified concentra-
tions. Serially diluted mAbs were mixed in equal volume with 
diluted virus. Antibody-virus and virus only mixtures were 
then incubated at 37°C with 5% CO2 for one hour. Following 
incubation, serially diluted mAbs and virus only controls 
were added in duplicate to the cells at 75 PFU at 37°C with 
5% CO2. After 24 hours, cells were lysed, and luciferase activ-
ity was measured via Nano-Glo Luciferase Assay System 
(Promega) according to the manufacturer specifications. Lu-
minescence was measured by a Spectramax M3 plate reader 
(Molecular Devices). Virus neutralization titers were defined 
as the sample dilution at which a 50% reduction in relative 
light units was observed relative to the average of the virus 
control wells. 
Lentivirus pseudovirus neutralization assay 
(PsVNA) 
The PsVNA using 293-ACE2-TMPRSS2 cell line was de-
scribed previously (38, 39). Antibody preparations were eval-
uated by SARS-CoV-2 PsVNA50 using WA-1 strain, B.1.1.7 
(with spike protein mutations: H69-V70del, Y144del, N501Y, 
A570D, D614G, P681H, T716I, S982A, and D1118H), B.1.429 
(with spike protein mutations S13I, W152C, L452R, D614G), 
B.1.526 (with spike protein mutations L5F, T95I, D253G,
E484K or S477N, D614G, A701V), P.1 (with spike protein mu-
tations L18F, T20N, P26S, D138Y, R190S, K417T, E484K,
N501Y, H655Y, T1027I, D614G, V1176F), B.1.351 (with spike
protein mutations L18F, D80A, D215G, L242-244del, K417N,
E484K, N501Y, D614G, and A701V), B.1.617.1 (with spike pro-
tein mutations G142D, E154K, V382L, L452R, E484Q, P681R,
Q1071H, D1153Y) and B.1.617.2 (with spike protein mutations
T19R, G142D, E156del, F157del, R158G, L452R, T478K, D614G,
P681R, D950N). Controls included cells only, virus without
any antibody and positive serum samples. The cut-off value
or the limit of detection (LoD) for the neutralization assay
was 1:10 dilution.
Surface plasmon resonance 
Kinetic measurements of the DH1047 Fab binding to 
SARS-CoV and RsSHC014 spike proteins were obtained using 
a Biacore S200 instrument (Cytiva, formerly GE Healthcare) 
in HBS-EP+ 1X running buffer. The spike proteins were first 
captured onto a Series S Streptavidin chip to 300 to 400 re-
sponse units (RU) for the SARS-CoV spike proteins and 850 
to 1000 RU for the RsSHC014 spike protein. The DH1047 Fab 
was diluted from 2.5 to 200nM and injected over the captured 
coronavirus spike proteins using the single cycle kinetics in-
jection type at a flow rate of 50μL per minute. There were five
120 s injections of the Fab at increasing concentrations fol-
lowed by a dissociation of 600 s after the final injection. After 
dissociation, the spike proteins were regenerated from the 
streptavidin surface using a 30 s pulse of Glycine pH1.5. Re-
sults were analyzed using the Biacore S200 Evaluation soft-
ware (Cytiva). A blank streptavidin surface along with blank 
buffer binding were used for double reference subtraction to 
account for non-specific protein binding and signal drift. 
Subsequent curve fitting analyses were performed using a 1:1 
Langmuir model with a local Rmax for the DH1047 Fab. The 
reported binding curves are representative of two data sets. 
Biolayer interferometry (BLI) 
Binding assays were performed by biolayer interferometry 
in an Octet RED384 instrument (Forte Bio). Anti-human IgG 
(AHQ) biosensor tips were dipped into 200 μl of filtered su-
pernatant DH1047 WT or mutant proteins for five minutes at 
1000 rpm followed by 1 min in 1X PBS. Next, the tips were 
dipped into 100 nM of purified SARS-CoV-2 2P spike ectodo-
main and binding response was measured. Non-specific bind-
ing was accounted for by using reference subtraction of signal 
on a senor tip captured with control mock transfection. Anal-
ysis was performed on Octet Data Analysis HT software 
(ForteBio) and visualization and normalization using Prism 
9. 
Protein expression and purification for EM studies 
The SARS-CoV spike ectodomain construct comprised the 
residues 1 to 1190 (UniProt P59594-1) with proline substitu-
tions at 968 to 969, a C-terminal T4 fibritin trimerization mo-
tif, a C-terminal HRV3C protease cleavage site, a 
TwinStrepTag and an 8XHisTag. The construct was cloned 
into the mammalian expression vector pαH (40). The
RsSHC014 spike ectodomain construct was prepared simi-
larly, except it also contained the 2P mutations that placed 
two consecutive proline at the HR1-CH junction at residue 
positions 986 and 987. FreeStyle 293F (Thermo Fisher Scien-
tific) cells were used for the spike ectodomain production. 
Cells were maintained in FreeStyle 293 Expression Medium 
(Gibco) at 37°C and 9% CO2, with agitation at 120 rpm in a 
75% humidified atmosphere. Transfections were performed 
as previously described (41, 42) using Turbo293 (SpeedBio-
systems). Sixteen to 18 hours post transfection, HyClone 
CDM4HEK293 media (Cytiva) was added. On the sixth day 
post transfection, spike ectodomain was harvested from the 
concentrated supernatant. The purification was performed 
using StrepTactin resin (IBA LifeSciences) and size exclusion 
chromatography (SEC) on a Superose 6 10/300 GL Increase 
column (Cytiva) in 2mM Tris, pH 8.0, 200 mM NaCl, 0.02% 
NaN3. All steps were performed at room temperature and the 
purified spike proteins were concentrated to 1 to 5 mg/ml, 
flash frozen in liquid nitrogen and stored at -80°C until fur-
ther use. 
DH1047 IgG was produced in Expi293F (Thermo Fisher 
Scientific) cells maintained in Expi293 Expression Medium 
(Gibco) at 37°C, 120 rpm, 8% CO2 and 75% humidity. Plasmids 
were transfected using the ExpiFectamine 293 Transfection 
Kit and protocol (Gibco) (41, 43) and purified by Protein A 
affinity (EMD Millipore). The IgG was digested to the Fab 
state using LysC (Thermo Fisher Scientific). 
Negative Stain Electron Microscopy (NSEM) 
NSEM was performed as described previously (15). Briefly, 
Fab-spike protein complexes were prepared by mixing Fab 
and spike to give a 9:1 molar ratio of Fab to spike protein. 
Following an incubation for 1 hour at 37°C, the complex was 
cross-linked by diluting to a final spike protein concentration 
of 0.1 mg/ml into room-temperature buffer containing 150 
mM NaCl, 20 mM HEPES pH 7.4, 5% glycerol, and 7.5 mM 
glutaraldehyde and incubating for 5 min. Excess glutaralde-
hyde was quenched by adding sufficient 1M Tris pH 7.4 stock 
to give a final concentration of 75 mM Tris and incubated for 
5 min. Carbon-coated grids (EMS, CF300-cu-UL) were glow-
discharged for 20 s at 15 mA, after which a 5-μl drop of
quenched sample was incubated on the grid for 10 to 15 s, 
blotted, and then stained with 2% uranyl formate. After air 
drying grids were imaged with a Philips EM420 electron mi-
croscope operated at 120 kV, at 82,000x magnification and 
images captured with a 2k × 2k CCD camera at a pixel size of 
4.02 Å. 
The RELION 3.0 program was used for all negative stain 
image processing. Images were imported, contrast transfer 
function (CTF)-corrected with CTFFIND, and particles were 
picked using a spike protein template from previous 2D class 
averages of spike protein alone. Extracted particle stacks 
were subjected to two to three rounds of 2D class averaging 
and selection to discard junk particles and background picks. 
Cleaned particle stacks were then subjected to 3D classifica-
tion using a starting model created from a bare spike protein 
model, PDB 6vsb, low-pass filtered to 30 Å. Classes that 
showed clearly defined Fabs were selected for final refine-
ments followed by automatic filtering and B-factor sharpen-
ing with the default Relion post-processing parameters. 
Cryo-EM 
Purified SARS-CoV-1 spike ectodomain was incubated for 
approximatively 2 hours with a 6-fold molar equivalent of the 
DH1047 Fab in a final volume of 10μL. The sample concen-
tration was adjusted to about 1.5 mg/mL of spike protein in 
2 mM Tris pH 8.0, 200 mM NaCl, and 0.02% NaN3. Before 
freezing, 0.1μL of glycerol was added to the 10μL of sample.
A 2.4 μL drop of protein was deposited on a Quantifoil-1.2/1.3
grid (Electron Microscopy Sciences) that had been glow dis-
charged for 10 s using a PELCO easiGlow Glow Discharge 
Cleaning System. After a 30 s incubation in greater than 95% 
humidity, excess protein was blotted away for 2.5 s before be-
ing plunge frozen into liquid ethane using a Leica EM GP2 
plunge freezer (Leica Microsystems). Frozen grids were 
imaged using a Titan Krios (Thermo Fisher Scientific) 
equipped with a K3 detector (Gatan). Data processing was 
performed using cryoSPARC (44). Model building and refine-
ment was done using Phenix (45, 46), Coot (47), Pymol (48), 
Chimera (49), ChimeraX (50) and Isolde (51). Similar to what 
we had observed for the DH1047 complex with the SARS-CoV-
2 spike ectodomain (15), there was considerable heterogene-
ity in the RBD region. Further classification of particles was 
performed to better resolve the antibody binding interface, 
resulting in an asymmetric reconstruction of a population re-
fined to a resolution of 3.4 Å that was used for model fitting. 
Animals and challenge viruses 
Eleven-month-old female BALB/c mice were purchased 
from Envigo (#047) and were used for the SARS-CoV, SARS-
CoV-2 B.1.351, and RsSHC014-CoV protection experiments. 
Eight to 10-week-old hACE2-transgenic mice (B6J.Cg-
Tg(FOXJ1-ACE2)1Rba/Mmnc) were bred at UNC Chapel Hill 
and were used for WIV-1-CoV protection experiments. The 
study was carried out in accordance with the recommenda-
tions for care and use of animals by the Office of Laboratory 
Animal Welfare (OLAW), National Institutes of Health and 
the Institutional Animal Care and Use Committee (IACUC) of 
University of North Carolina (UNC permit no. A-3410-01). An-
imals were housed in groups of five and fed standard chow 
diets. Virus inoculations were performed under anesthesia 
and all efforts were made to minimize animal suffering. All 
mice were anesthetized by injecting xylazine and ketamine 
intraperitoneally and infected intranasally with 1 × 104 
PFU/ml of SARS-CoV MA15, 1 × 104 PFU/ml of SARS-CoV-2 
B.1.351-MA10, 1 × 104 PFU/ml RsSHC014 or 1 × 104 PFU/ml
WIV-1, which have been described previously (6, 52, 53). Mice
were weighted daily and monitored for signs of clinical dis-
ease, and selected groups were subjected to daily whole-body
plethysmography. For all mouse studies, groups of n=10 mice
were included per arm of the study except for the hACE2-
transgenic mice, which included n=5 mice per group due to
a limited availability of these mice. Viral titers, weight loss,
and histology were measured from individual mice per group.
Lung pathology scoring 
Acute lung injury was quantified by two separate lung pa-
thology scoring scales: Matute-Bello and Diffuse Alveolar 
Damage (DAD) scoring systems. Analyses and scoring were 
performed by a board certified veterinary pathologist who 
was blinded to the treatment groups as described previously 
(54). Lung pathology slides were read and scored at 600X to-
tal magnification. 
The lung injury scoring system used is from the American 
Thoracic Society (Matute-Bello) to help quantitate histologi-
cal features of ALI observed in mouse models to relate this 
injury to human settings. In a blinded manner, three random 
fields of lung tissue were chosen and scored for the following: 
(A) neutrophils in the alveolar space (none = 0, 1 to 5 cells =
1, greater than 5 cells = 2), (B) neutrophils in the interstitial 
septa (none = 0, 1 to 5 cells = 1, greater than 5 cells = 2), (C) 
hyaline membranes (none = 0, one membrane = 1, greater 
than 1 membrane = 2), (D) Proteinaceous debris in air spaces 
(none = 0, one instance = 1, greater than 1 instance = 2), (E) 
alveolar septal thickening (less than 2x mock thickness = 0, 2 
to 4x mock thickness = 1, greater than 4x mock thickness = 
2). To obtain a lung injury score per field, A to E scores were 
put into the following formula score = [(20x A) + (14 x B) + (7 
x C) + (7 x D) + (2 x E)]/100. This formula contains multipliers 
that assign varying degrees of importance for each phenotype 
of the disease state. The scores for the three fields per mouse 
were averaged to obtain a final score ranging from 0 to and 
including 1. The second histology scoring scale to quantify 
acute lung injury was adopted from a lung pathology scoring 
system from lung RSV infection in mice (55). This lung his-
tology scoring scale measures diffuse alveolar damage (DAD). 
Like the implementation of the ATS histology scoring scale, 
three random fields of lung tissue were scored for the follow-
ing in a blinded manner: 1= absence of cellular sloughing and 
necrosis, 2=uncommon solitary cell sloughing and necrosis (1 
to 2 foci per field), 3=multifocal (3+foci) cellular sloughing 
and necrosis with uncommon septal wall hyalinization, or 
4=multifocal (greater than 75% of field) cellular sloughing 
and necrosis with common or prominent hyaline mem-
branes. The scores for the three fields per mouse were aver-
aged to get a final DAD score per mouse. The microscope 
images were generated using an Olympus Bx43 light micro-
scope and CellSense Entry v3.1 software. 
Weblogo 
As the interface in the SARS-CoV-2/DH1047 complex was 
better resolved (15), we used this complex for visualizing 
epitope details and analyzing extent of conservation of the 
epitope residues in different sarbecoviruses. The Weblogo 
tool from UC Berkeley was used to generate the consensus 
epitopes of the DH1047 HCDR3 and LCDR3 epitopes. 
https://weblogo.berkeley.edu/logo.cgi . The following 23 sar-
becovirus genomes were used for the Weblogo analysis: 
KT444582, AY278554, AY278741, AY515512, AY525636, 
KC881005, KC881006, KF367457, MK211376, MN908947, 
MN996532, MG772933, MG772934, MK211374, DQ412042, 
DQ648856, MK211378, DQ022305, DQ412043, DQ648857, 
DQ071615, MK211375, MK211377. 
Statistics 
A two-way ANOVA followed by Tukey’s multiple compar-
isons test to adjust for false discovery rates, a one-way 
ANOVA followed by Dunnett’s multiple comparisons to ad-
just for false discovery rates, or a Mantel-Cox test were used 
in mouse experiment measurements. See figure legends for 
details. All statistical analyses were performed using 
GraphPad Prism 9. 
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Fig. 1. The identification of broadly neutralizing antibodies. (A) The genetic relationships of 
ACE2 and non-ACE2 using sarbecovirus receptor binding domains is shown. SARS-CoV-2 2AA 
MA is shown in purple, SARS-CoV is shown in orange, WIV-1 is shown in pink, and RsSHC014 is 
shown in green. The scale bar indicates the genetic distance scale among sarbecoviruses of 25%. 
The neutralization activity against sarbecoviruses is shown for DH1235 (B), DH1073 (C), DH1046 
(D), and DH1047 (E). Data are representative of two technical replicates. 
Fig. 2. The binding 
breadth and structural 
determinants of broad 
neutralization. (A to D) 
The binding activity of 
cross-reactive antibodies 
was measured against 
SARS-CoV spike protein, 
SARS-CoV-2 spike protein, 
SARS-CoV-2 RBD, 
Pangolin GXP4L spike 
protein, RaTG13 spike 
protein, and RsSHC014 
spike protein. The 
antibodies tested were 
DH1235 (A), DH1073 (B), 
DH1046 (C), and DH1047 
(D). (E) A cryo-EM 
reconstruction of DH1047 
Fab bound to SARS-CoV 
spike protein is shown. 
Spike protein is shown in 
gray, with the underlying 
fitted model shown in 
cartoon representation. 
DH1047 is colored green 
and the RBD it is bound to 
is colored black, with the 
receptor binding motif 
within the RBD colored 
purple. An overlay of 
DH1047 bound to SARS-
CoV-1 and SARS-CoV-2 
(PDB ID: 7LDI) spike 
proteins is shown in the 
middle panel. Overlay was 
performed with the 
respective RBDs. DH1047 
bound to SARS-CoV and 
SARS-CoV-2 spike protein 
are shown in green and 
salmon, respectively. ACE2 
(yellow surface 
representation, PDB 
6VW1) binding to RBD is 
sterically hindered by 
DH1047. The views in 
panels B and C are related 
by a 180° rotation about 
the vertical axis. (F) 
Sequence conservation 
within the DH1047 HCDR3 
and LCDR3s is shown 
among 23 sarbecoviruses. 
Fig. 3. Prevention and 
therapy of DH1047 
against SARS-CoV in aged 
mice. (A) SARS-CoV 
mouse-adapted 15 (MA15) 
lung viral replication is 
shown. Mice (n=5 per 
group) treated 12 hours 
before infection with a 
control influenza mAb 
CH65 or one of the four 
broadly neutralizing 
antibodies DH1235,
DH1073, DH1046, DH1047. 
Days post infection, dpi, 
limit of detection LoD; 
plaque forming units, PFU. 
(B) The percentage of
starting weight is shown for 
mice (n=10 per group)
treated prophylactically (12 
hours before infection) or
therapeutically (12 hours
after infection) with
DH1047 or control and
challenged with SARS-CoV
MA15. Data are presented
as mean±SEM. (C) Lung
viral replication of SARS-




DH1047 and control at 4 
days post infection. (D) 
Macroscopic lung 
discoloration scores are 
shown for mice treated 
with DH1047 or control 
antibody prophylactically 
and therapeutically. (E) 
Lung pathology at day 4 
post infection was 
measured by acute lung 
injury (ALI) scores in mice 
treated with DH1047 or 
control prophylactically  
and therapeutically. (F) Lung pathology at day 4 post infection was measured by diffuse alveolar damage (DAD) in 
mice treated prophylactically  and therapeutically with DH1047 and control. (G) Pulmonary function was measured 
by whole body plethysmography in mice treated with DH1047 or control mAb prophylactically or therapeutically. (H) 
Percent survival is shown for mice treated with control or DH1047 prophylactically or therapeutically and challenged 
with SARS-CoV MA15. Horizontal bars in (A) and (C to G) indicate mean. P-values shown in (B and G) were calculated 
using a two-way ANOVA followed by Tukey’s multiple comparisons test. P-values are for (A) and (C to E) were 
calculated using a one-way ANOVA followed by Dunnett’s multiple comparisons. P values for (H) were calculated 
using a Mantel-Cox test. **p<0.01; ***p<0.001; ****p<0.0001. 
Fig. 4. Prophylactic and therapeutic activity of DH1047 against SARS-related bat coronaviruses and 
the in vitro neutralization against the SARS-CoV-2 variants. (A) Lung viral replication of WIV-1 is shown 
for mice (n=4 to 5 per group) treated prophylactically or therapeutically with DH1047 or control at 2 days 
post infection. Horizontal bars indicate mean. (B) Lung viral replication of RsSHC014 is shown for mice 
(n=5 to 10 per group) treated prophylactically or therapeutically with DH1047 or control at 2 days post 
infection. Horizontal bars indicate mean. (C) Live virus neutralization of SARS-CoV-2 D614G, B.1.1.7, and 
B.1.351 variants by DH1047 is shown. Data are representative of two technical replicates. (D) The
comparison of the DH1047 neutralization activity against SARS-CoV-2 variants is shown for pseudovirus
and live virus neutralization assays. NT, not tested. P-values in (A) and (B) were calculated using a one-
way ANOVA followed by Dunnett’s multiple comparisons test. *p<0.05; **p<0.01.

Fig. 5. Prophylaxis and therapy of DH1047 against SARS-CoV-2 B.1.351 in mice. (A) Percent of 
starting weight is shown for mice (n=10 per group) treated prophylactically (12 hours before infection) 
or therapeutically (12 hours after infection) with DH1047 or control antibody and challenged with 
SARS-CoV-2 B.1.351. (B) Lung viral replication is shown at 4 days post infection for mice infected with 
SARS-CoV-2 B.1.351 and treated prophylactically or therapeutically with DH1047 or control. (C) 
Macroscopic lung discoloration scores are shown at 4 days post infection for mice infected with SARS-
CoV-2 B.1.351 and treated prophylactically or therapeutically with DH1047 or control. (D) Lung 
pathology measured by acute lung injury (ALI) scores is shown at 4 days post infection for mice 
infected with SARS-CoV-2 B.1.351 and treated prophylactically or therapeutically with DH1047 or 
control. (E) Lung pathology measured by diffuse alveolar damage (DAD) is shown at 4 days post 
infection for mice infected with SARS-CoV-2 B.1.351 and treated prophylactically or therapeutically 
with DH1047 or control. (F) Percent survival is shown for SARS-CoV-2 B.1.351-infected mice treated 
with DH1047 prophylactically or therapeutically with DH1047 or control. (G) Percent of starting weight 
is shown for mice (n=10 per group) treated prophylactically with DH1047 (12 hours before infection) at 
de-escalating doses of 10, 5, and 1mg/kg or with 10mg/kg control mAb, CH065. (H) Lung viral titers in 
control and DH1047-treated mice at 10, 5, and 1mg/kg. (I) Lung discoloration in control and DH1047-
treated mice at the various mAb doses. Data in (A and G) are presented as mean±SEM. Horizontal bars 
in (B to E) and (H and I) represent mean. P-values shown in (A and G) are from a two-way ANOVA 
followed by Tukey’s multiple comparisons test, and P-values shown in (B to E) and (H and I) are from a 
one-way ANOVA followed by Dunnett’s multiple comparisons test. Differences in survival were 
measured by a Mantel-Cox test. **p<0.01; ***p<0.001; ****p<0.001; ns, not significant. (J) DH1047 
binding is shown relative to binding of other known antibody classes that bind the RBD. RBD is shown 
in black with the ACE2 footprint on the RBD colored yellow. DH1047 is shown in cartoon representation 
and colored green. The other antibodies are shown as transparent surfaces: C105 (pale cyan, Class 1, 
PDB ID: 6XCN and 6XCA), DH1041 (light blue, Class 2, PDB ID: 7LAA), S309 (wheat, Class 3, PDB 
ID:6WS6 and 6WPT) and CR3022 (pink, Class 4, PDB ID: 6YLA) 
